Holen Sie sich die Stockscreener-App
0.87
0.81%
0.007
Handel nachbörslich:
.87
Schlusskurs vom Vortag:
$0.863
Offen:
$0.8612
24-Stunden-Volumen:
26,980
Relative Volume:
0.23
Marktkapitalisierung:
$17.88M
Einnahmen:
$31.56M
Nettoeinkommen (Verlust:
$-46.89M
KGV:
-0.2869
EPS:
-3.0329
Netto-Cashflow:
$-26.70M
1W Leistung:
-6.45%
1M Leistung:
-30.95%
6M Leistung:
-52.72%
1J Leistung:
-72.03%
1-Tages-Spanne:
$0.8612
$0.9499
1-Wochen-Bereich:
$0.8011
$0.9699
52-Wochen-Spanne:
$0.8011
$3.47
Casi Pharmaceuticals Inc Stock (CASI) Company Profile
Firmenname
Casi Pharmaceuticals Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie CASI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CASI
Casi Pharmaceuticals Inc
|
0.87 | 17.73M | 31.56M | -46.89M | -26.70M | -3.0329 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Casi Pharmaceuticals Inc Stock (CASI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-05-18 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Eingeleitet | Mizuho | Buy |
| 2020-10-23 | Eingeleitet | Oppenheimer | Outperform |
| 2016-09-22 | Eingeleitet | Maxim Group | Buy |
| 2015-10-29 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-23 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Casi Pharmaceuticals Inc Aktie (CASI) Neueste Nachrichten
Aug PreEarnings: Is CASI Pharmaceuticals Inc stock a contrarian buyJuly 2025 Analyst Calls & Growth Focused Stock Pick Reports - moha.gov.vn
CASI Pharmaceuticals, Inc. announced that it expects to receive $20 million in funding from Emerging Technology Partners, LLC - marketscreener.com
CASI Pharmaceuticals secures $20 million funding for transplant rejection study - Investing.com
CASI Pharmaceuticals Secures $20 Million for Renal AMR Study - TipRanks
CASI Pharmaceuticals secures $20 million funding for transplant rejection study By Investing.com - Investing.com South Africa
CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing - The Joplin Globe
CASI Pharmaceuticals (NASDAQ: CASI) plans $20 million notes to fund China AMR trial - Stock Titan
CASI Pharmaceuticals reports positive phase 1 data for ITP treatment - Investing.com
CASI Pharmaceuticals reports positive phase 1 data for ITP treatment By Investing.com - Investing.com Australia
CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting - ACCESS Newswire
Casi Pharmaceuticals announces CID-103 immune thrombocytopenia study results - MSN
How sustainable is CASI Pharmaceuticals Inc. stock dividend payoutEarnings Trend Report & Verified Technical Trade Signals - Newser
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES - GuruFocus
CASI Pharmaceuticals, Inc. (CASI) 6.93% in After-hours: What’s Driving the Move? - Stocks Telegraph
Hedge Fund Moves: What margin trends mean for CASI Pharmaceuticals Inc. stockWeekly Profit Analysis & Weekly Watchlist for Hot Stocks - moha.gov.vn
CASI Pharmaceuticals Announces Changes in Board Governance - Investing News Network
CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results - Investing News Network
CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ - Investing News Network
Lacklustre Performance Is Driving CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) 27% Price Drop - simplywall.st
CASI Pharmaceuticals Inc. (CASI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Casi Pharmaceuticals appoints James Huang as non-executive chairman - MSN
CASI Pharmaceuticals Appoints James Huang as Non-Executive Chairman - The Globe and Mail
How resilient is CASI Pharmaceuticals Inc. stock in market downturns2025 Key Lessons & Long-Term Capital Growth Strategies - newser.com
How CASI Pharmaceuticals Inc. stock performs in weak economyGap Up & Daily Growth Stock Tips - newser.com
How to read the order book for CASI Pharmaceuticals Inc.2025 Market Outlook & Weekly Top Gainers Alerts - newser.com
Is CASI Pharmaceuticals Inc. stock gaining market shareJuly 2025 Trends & Growth Oriented Trade Recommendations - newser.com
Is CASI Pharmaceuticals Inc. stock a top momentum playMarket Performance Summary & Weekly High Potential Alerts - newser.com
[6-K] CASI Pharmaceuticals, Inc. Current Report (Foreign Issuer) | CASI SEC FilingForm 6-K - Stock Titan
CASI Pharmaceuticals (NASDAQ: CASI) appoints James Huang Non-Executive Chairman - Stock Titan
CASI Pharmaceuticals Names James Huang Non-Executive Chairman of Board - marketscreener.com
What MACD and RSI say about CASI Pharmaceuticals Inc.2025 Macro Impact & Fast Entry Momentum Alerts - newser.com
Smart tools for monitoring CASI Pharmaceuticals Inc.’s price actionTrade Analysis Summary & Safe Swing Trade Setups - newser.com
Is CASI Pharmaceuticals Inc. stock attractive for retirement portfoliosTrade Performance Summary & Consistent Profit Focused Trading Strategies - newser.com
Can CASI Pharmaceuticals Inc. stock resist sector downturnsBuy Signal & Expert Approved Momentum Trade Ideas - newser.com
Will CASI Pharmaceuticals Inc. stock attract more institutional investorsChart Signals & Capital Protection Trade Alerts - newser.com
CASI Pharmaceuticals Stumbles On Revenue Drop And Nasdaq Challenge - Finimize
CASI Pharmaceuticals Reports Q3 2025 Results Amid Nasdaq Delisting Appeal - MSN
Finanzdaten der Casi Pharmaceuticals Inc-Aktie (CASI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.36%
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):